Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 8, 2008, Pages 1063-1069

  Barrios, Vivencio ^a   Escobar, Carlos ^b   Divison, Juan Antonio ^c   Medialdea, Francísco ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c Primary Health Care Centre   (Spain)

^d Medical Department   (Spain)

Author keywords

Combined therapy; Diabetes; Hypertension; Indapamide; Perindopril

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE PLUS PERINDOPRIL; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC HYPERTENSION; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; PATIENT SATISFACTION; PRESCRIPTION; RISK FACTOR; SMOKING;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; PERINDOPRIL; TREATMENT OUTCOME;

EID: 55249102423     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.8.1063     Document Type: Article

References (31)

1. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 28(1), 88-136 (2007).
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes; estimates for year 2000 and projections for 2030. Diabetes Care 21(5), 1047-1053 (2004).
3. Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. Cardiovascular risk factors in Spanish population: meta-analysis of cross-sectional studies. Med. Clin. (Barc.) 124(16), 606-612 (2005).
4. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann. Intern. Med. 125(4), 304-310 (1996).
5. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21(6), 1011-1053 (2003).
6. Chobanian AV, Bakris GL, Black HR et al. the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
7. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25 (6), 1105-1187 (2007).
8. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 362 (9395), 1527-1535 (2003).
9. Barrios V. Escobar C, Calderon A et al. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J. Clin. Hypertens. 9(5), 324-329 (2007).
10. Escobar C, Barrios V, Calderón A et al. Diabetes mellitus in hypertensive population attended in Primary Care in Spain. Blood pressure and lipid control rates. Rev. Clin. Esp. 207(5), 221-227 (2007).
11. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (23), 2981-2997 (2002).
12. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch. Intern. Med. 165(12), 1410-1419 (2005).
13. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy. Lancet 355 (9200), 253-259 (2000).
14. Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 370(9590), 829-840 (2007).
15. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342 (25), 1887-1892 (2000).
16. Steg PG, Lopez-Sendon J, Lopez de Sa E et al. External validity of clinical trials in acute myocardial infarction. Arch. Intern. Med. 167(1), 68-73 (2007).
17. Barrios V, Escobar C, Calderón A et al. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J. Hum. Hypertens. 21(6), 479-485 (2007).
18. Cifkova R, Erdine S, Fagard R et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J. Hypertens. 21(10), 1779-1786 (2003).
19. Barrios V, Escobar C, Navarro A, Barrios L, Navarro-Cid J, Calderón A. Lercanidipine is an effective and well tolerated antihypertensive drug regardless of the cardiovascular risk profile. The LAURA study. Int. J. Clin. Pract. 60 (11), 1364-1370 (2006).
20. Barrios V, Escobar C, Divison JA, Medialdea F. Clinical experience with a low-dose fixed combination of perindopril plus indapamide in a primary care setting. Findings from the PRETEND study. Therapy 4(5), 677-683 (2008).
21. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension 37(4), 1053-1059 (2001).
22. Myers MG, Leenen FH. The impact of one or two missed doses on the duration of action of combined perindopril and indapamide. J. Hum. Hypertens. 21(1), 86-93 (2007).
23. Holland N, Segraves D, Nnadi VO et al. Identifying barriers to hypertension care: implications for quality improvement initiatives. Dis. Manag. 11 (2), 71-77 (2008).
24. Vinker S, Alkalay A, Hoffman RD et al. Long-term adherence to antihypertensive therapy: a survey in four primary care clinics. Expert Opin. Pharmacother. 9(8), 1271-1277 (2008).
25. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62(3), 443-462 (2002).
26. Dahlof B, Gosse P, Gueret P et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J. Hypertens. 23(11), 2063-2070 (2005).
27. Mogensen CE, Viberti G, Halimi S et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Hypertension 41(5), 1063-1071 (2003).
28. Mallion JM, Chamontin B, Asmar R et al. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am. J. Hypertens. 17(3), 245-251 (2004).
29. Laurent S. Very-low-dose combination of perindopril and indapamide: efficacy on blood pressure and target-organ damage. J. Hypertens. Suppl. 21(3), 11-18 (2003).
30. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J. Hypertens. 22 (8), 1623-1630 (2004).
31. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J. Am. Coll. Cardiol. 43(1), 92-99 (2004).